Advertisement
U.S. markets closed

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.78-0.08 (-0.67%)
At close: 04:00PM EDT
12.14 +0.36 (+3.06%)
After hours: 04:50PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Continuation Wedge (Bullish)

Continuation Wedge (Bullish)

Previous Close11.86
Open11.87
Bid11.72 x 500
Ask11.78 x 500
Day's Range11.48 - 11.93
52 Week Range9.70 - 14.57
Volume2,399,468
Avg. Volume3,129,267
Market Cap3.48B
Beta (5Y Monthly)0.76
PE Ratio (TTM)N/A
EPS (TTM)-0.51
Earnings DateMay 08, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FOLD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amicus Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/28/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • GlobeNewswire

    Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report

    PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year’s report highlights the strength of the Company’s corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensu

  • Insider Monkey

    13 Best Biotech Stocks To Buy Under $20

    In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]

  • GuruFocus.com

    Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)

    Director Margaret Mcglynn has sold 15,000 shares of Amicus Therapeutics Inc (NASDAQ:FOLD) on March 5, 2024, according to a recent SEC Filing.